Pamplona Capital $4.5 billion acquisition of Parexel

Overview:

• Investment management firm Pamplona Capital has acquired US pharmaceutical research services provider Parexel for $4.5 billion.
• Pamplona is also assuming $500 million of Parexel's debt.
• The deal comes in the wake of Pamplona's unsuccessful bid for US clinical trials firm Pharmaceutical Product Development, which was valued at more than $9 billion.
• Goldman Sachs was Parexel's financial adviser, while Perella Weinberg Partners acted for Pamplona. 
• The deal is expected to close in the fourth quarter of 2017.

Katrin Kostadinova - Data analyst